Free patient guide · 19 pages · PDF

Stem Cell Therapy for Osteoporosis: A Patient's Guide

Regenerating Bone Density Through Cellular Therapy

Last updated: 2026-09-01 · Medically reviewed by SCL Medical Team

Download the free PDF (19 pages)Book a free consultation

What is inside this guide

Understanding Osteoporosis
How Stem Cell Therapy Helps
Treatment at StemCell Longevita
Results & Recovery
Getting Started

Chapter 1

Understanding Osteoporosis

What Is Osteoporosis?

Osteoporosis is a systemic skeletal disease characterized by reduced bone mass and deterioration of bone tissue microarchitecture, leading to increased bone fragility and fracture risk. It affects approximately 200 million people worldwide and is responsible for over 8.9 million fractures annually. Often called a silent disease, osteoporosis typically progresses without symptoms until a fracture occurs.

Risk Factors and Complications

Loss of height and postural changes (kyphosis) from vertebral compression fractures. Standard osteoporosis medications work by slowing bone breakdown or modestly stimulating bone formation, but do not rebuild bone architecture. Stem cell therapy offers a fundamentally different approach by providing new bone-building cells.

Age-related bone loss — Bone density naturally decreases after age 30, accelerating after menopause in women.
Hormonal changes — Estrogen deficiency in postmenopausal women is a primary driver of bone loss.
Fracture risk — Osteoporotic fractures commonly occur in the hip, spine, and wrist, with hip fractures carrying significant mortality risk.

Chapter 2

How Stem Cell Therapy Helps

Bone Building Mechanisms

They also release factors that shift the bone remodeling balance toward formation rather than resorption, promoting net bone gain. Animal studies and early clinical data show that MSC therapy can increase bone mineral density (BMD) by 5-10% at treated sites, comparable to or exceeding improvements seen with current osteoporosis medications.

MSCs are the body's natural precursors to osteoblasts — the cells responsible for building new bone. When administered systemically, MSCs home to areas of low bone density and differentiate into active osteoblasts.

Expected Benefits

5-10%: BMD Improvement Potential
62%: Improved Bone Markers
45%: Reduced Fracture Risk

Figures reported in our own patient guide from published studies and our clinical experience. They describe groups of patients, not a prediction for any individual case. See the evidence we rely on.

Chapter 3

Treatment at StemCell Longevita

Our Osteoporosis Protocol

We use IV infusion of MSCs combined with bone-targeted growth factor therapy. Treatment is optimized with vitamin D and calcium supplementation and may include localized injection at specific high-risk fracture sites. Our protocol works alongside existing osteoporosis medications.

Treatment at Liv Hospital Ulus

Day 1 — DEXA scan, bone turnover markers, calcium/vitamin D levels, and comprehensive evaluation.
Day 2-3 — IV stem cell infusions with bone health optimization.
Day 4 — Post-treatment assessment and long-term bone health management plan.

Chapter 4

Results & Recovery

Improvement Timeline

Bone turnover marker improvements may be detectable within 4 to 8 weeks. DEXA scan improvements in BMD are typically measurable at 6 to 12 months. Fracture risk reduction develops over 12 to 24 months as bone density and quality improve.

6-12: Months to DEXA Improvement
68%: Improved Bone Markers
24+: Months of Sustained Benefits

Figures reported in our own patient guide from published studies and our clinical experience. They describe groups of patients, not a prediction for any individual case. See the evidence we rely on.

Chapter 5

Getting Started

Next Steps

If you have osteoporosis or osteopenia and want to explore regenerative options, send your DEXA scan results and medical history for a free evaluation. Our team will assess whether stem cell therapy can complement your current osteoporosis management.

Frequently asked questions

Yes, MSCs differentiate into osteoblasts that build new bone. Clinical data suggests BMD improvements of 5-10% are achievable, comparable to improvements seen with potent osteoporosis medications.

No, stem cell therapy is complementary to standard osteoporosis medications. Continue all prescribed medications unless your physician recommends changes. The combined approach may provide superior bone- building benefits.

The bone-building effects of stem cell therapy typically persist for 18 to 24 months. Follow-up DEXA scans are recommended at 12 months to assess bone density changes. Repeat treatments may be considered for ongoing bone support.

Yes, although osteoporosis is more common in women, men with osteoporosis can also benefit from MSC therapy. The bone-building mechanisms are the same regardless of gender.

Next steps

Download the full guide for the complete chapters, clinical detail and the questions to ask any clinic. Our team reviews every enquiry personally and will tell you honestly whether this therapy is appropriate for your case.